257 related articles for article (PubMed ID: 26917486)
21. Lanreotide Autogel in the Treatment of Idiopathic Refractory Diarrhea: Results of an Exploratory, Controlled, Before and After, Open-label, Multicenter, Prospective Clinical Trial.
Bisschops R; De Ruyter V; Demolin G; Baert D; Moreels T; Pattyn P; Verhelst H; Lepoutre L; Arts J; Caenepeel P; Ooghe P; Codden T; Maisonobe P; Petrens E; Tack J
Clin Ther; 2016 Aug; 38(8):1902-1911.e2. PubMed ID: 27423779
[TBL] [Abstract][Full Text] [Related]
22. Antiproliferative effects of lanreotide autogel in patients with progressive, well-differentiated neuroendocrine tumours: a Spanish, multicentre, open-label, single arm phase II study.
Martín-Richard M; Massutí B; Pineda E; Alonso V; Marmol M; Castellano D; Fonseca E; Galán A; Llanos M; Sala MA; Pericay C; Rivera F; Sastre J; Segura A; Quindós M; Maisonobe P;
BMC Cancer; 2013 Sep; 13():427. PubMed ID: 24053191
[TBL] [Abstract][Full Text] [Related]
23. The treatment of neuroendocrine tumors with long-acting somatostatin analogs: a single center experience with lanreotide autogel.
Bianchi A; De Marinis L; Fusco A; Lugli F; Tartaglione L; Milardi D; Mormando M; Lassandro AP; Paragliola R; Rota CA; Della Casa S; Corsello SM; Brizi MG; Pontecorvi A
J Endocrinol Invest; 2011 Oct; 34(9):692-7. PubMed ID: 22067307
[TBL] [Abstract][Full Text] [Related]
24. Lanreotide in metastatic enteropancreatic neuroendocrine tumors.
Caplin ME; Pavel M; Ćwikła JB; Phan AT; Raderer M; Sedláčková E; Cadiot G; Wolin EM; Capdevila J; Wall L; Rindi G; Langley A; Martinez S; Blumberg J; Ruszniewski P;
N Engl J Med; 2014 Jul; 371(3):224-33. PubMed ID: 25014687
[TBL] [Abstract][Full Text] [Related]
25. Pharmacokinetics of a new Autogel formulation of the somatostatin analogue lanreotide after a single subcutaneous dose in healthy volunteers.
Antonijoan RM; Barbanoj MJ; Cordero JA; Peraire C; Obach R; Vallès J; Chérif-Cheikh R; Torres ML; Bismuth F; Montes M
J Pharm Pharmacol; 2004 Apr; 56(4):471-6. PubMed ID: 15099442
[TBL] [Abstract][Full Text] [Related]
26. Systemic Treatment Options for Carcinoid Syndrome: A Systematic Review.
Wolin EM; Benson Iii AB
Oncology; 2019; 96(6):273-289. PubMed ID: 31018209
[TBL] [Abstract][Full Text] [Related]
27. Anti-tumour effects of lanreotide for pancreatic and intestinal neuroendocrine tumours: the CLARINET open-label extension study.
Caplin ME; Pavel M; Ćwikła JB; Phan AT; Raderer M; Sedláčková E; Cadiot G; Wolin EM; Capdevila J; Wall L; Rindi G; Langley A; Martinez S; Gomez-Panzani E; Ruszniewski P;
Endocr Relat Cancer; 2016 Mar; 23(3):191-9. PubMed ID: 26743120
[TBL] [Abstract][Full Text] [Related]
28. Effects of lanreotide Autogel primary therapy on symptoms and quality-of-life in acromegaly: data from the PRIMARYS study.
Caron PJ; Bevan JS; Petersenn S; Houchard A; Sert C; Webb SM;
Pituitary; 2016 Apr; 19(2):149-57. PubMed ID: 26603536
[TBL] [Abstract][Full Text] [Related]
29. TELEPRO: Patient-Reported Carcinoid Syndrome Symptom Improvement Following Initiation of Telotristat Ethyl in the Real World.
Strosberg J; Joish VN; Giacalone S; Perez-Olle R; Fish-Steagall A; Kapoor K; Dharba S; Lapuerta P; Benson AB
Oncologist; 2019 Nov; 24(11):1446-1452. PubMed ID: 31189618
[TBL] [Abstract][Full Text] [Related]
30. Population Pharmacokinetic Analysis of Lanreotide Autogel/Depot in the Treatment of Neuroendocrine Tumors: Pooled Analysis of Four Clinical Trials.
Buil-Bruna N; Garrido MJ; Dehez M; Manon A; Nguyen TX; Gomez-Panzani EL; Trocóniz IF
Clin Pharmacokinet; 2016 Apr; 55(4):461-73. PubMed ID: 26416534
[TBL] [Abstract][Full Text] [Related]
31. Clinical utility of lanreotide Autogel
Paragliola RM; Prete A; Papi G; Torino F; Corsello A; Pontecorvi A; Corsello SM
Drug Des Devel Ther; 2016; 10():3459-3470. PubMed ID: 27822010
[TBL] [Abstract][Full Text] [Related]
32. Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue.
Kvols LK; Moertel CG; O'Connell MJ; Schutt AJ; Rubin J; Hahn RG
N Engl J Med; 1986 Sep; 315(11):663-6. PubMed ID: 2427948
[TBL] [Abstract][Full Text] [Related]
33. Gluteal nodules in patients with metastatic midgut carcinoid disease treated with depot somatostatin analogs.
Debono M; Hon LQ; Bax N; Blakeborough A; Newell-Price J
J Clin Endocrinol Metab; 2008 May; 93(5):1860-4. PubMed ID: 18303072
[TBL] [Abstract][Full Text] [Related]
34. Effectiveness and tolerability of 3-year lanreotide Autogel treatment in patients with acromegaly.
Caron P; Cogne M; Raingeard I; Bex-Bachellerie V; Kuhn JM
Clin Endocrinol (Oxf); 2006 Feb; 64(2):209-14. PubMed ID: 16430722
[TBL] [Abstract][Full Text] [Related]
35. Lanreotide autogel every 6 weeks compared with Lanreotide microparticles every 3 weeks in patients with well differentiated neuroendocrine tumors: a Phase III Study.
Bajetta E; Procopio G; Catena L; Martinetti A; De Dosso S; Ricci S; Lecchi AS; Boscani PF; Iacobelli S; Carteni G; De Braud F; Loli P; Tartaglia A; Bajetta R; Ferrari L
Cancer; 2006 Nov; 107(10):2474-81. PubMed ID: 17054107
[TBL] [Abstract][Full Text] [Related]
36. Efficacy of the new long-acting formulation of lanreotide (lanreotide Autogel) in the management of acromegaly.
Caron P; Beckers A; Cullen DR; Goth MI; Gutt B; Laurberg P; Pico AM; Valimaki M; Zgliczynski W
J Clin Endocrinol Metab; 2002 Jan; 87(1):99-104. PubMed ID: 11788630
[TBL] [Abstract][Full Text] [Related]
37. A Patient-Reported Outcomes Analysis Of Lanreotide In The Treatment Of NETs Patients With Carcinoid Syndrome: Evidence From The ELECT Trial.
Blot K; Duchateau L; Lescrauwaet B; Liyanage N; Ray D; Mirakhur B; Vinik AI
Patient Relat Outcome Meas; 2019; 10():335-343. PubMed ID: 31754316
[TBL] [Abstract][Full Text] [Related]
38. Carcinoid syndrome. Medical management.
Clarke B; Hodgson HJ
Br J Hosp Med; 1986 Mar; 35(3):146-8, 150, 152. PubMed ID: 3742126
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of the efficacy and safety of lanreotide in combination with targeted therapies in patients with neuroendocrine tumours in clinical practice: a retrospective cross-sectional analysis.
Capdevila J; Sevilla I; Alonso V; Antón Aparicio L; Jiménez Fonseca P; Grande E; Reina JJ; Manzano JL; Alonso Lájara JD; Barriuso J; Castellano D; Medina J; López C; Segura Á; Carrera S; Crespo G; Fuster J; Munarriz J; García Alfonso P
BMC Cancer; 2015 Jul; 15():495. PubMed ID: 26138480
[TBL] [Abstract][Full Text] [Related]
40. [Somatuline(R) Autogel(R), a new formulation of lanreotide for the treatment of acromegalic patients].
Caron P
Ann Endocrinol (Paris); 2002 Apr; 63(2 Pt 3):2S19-24. PubMed ID: 12037499
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
